Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study. Issue 9 (2nd September 2017)

• Record Type: Journal Article
• Authors: de Vries, Joost C.; Oortgiesen, Berdien; Hemmelder, Marc H.; van Roon, Eric; Kibbelaar, Robby E.; Veeger, Nic; Hoogendoorn, Mels
• Is Part Of: Leukemia & lymphoma. Volume 58:Issue 9(2017)
• Page Start: 2101
• Page End: 2109
• Publication Date: 2017-09-02
• Subjects: Multiple myeloma -- renal impairment -- renal response -- novel treatment -- overall survival -- dialysis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2016.1277385
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Renal impairment (RI) in patients with multiple myeloma (MM) is associated with poor prognosis. In this population-based cohort study, we assessed the effects of renal response, evaluated according to the IMWG-criteria, on overall survival (OS) in patients with newly diagnosed MM with RI at presentation. All included patients were diagnosed between January 2005 and January 2014 with MM and RI in Friesland, a province of the Netherlands. Of the 131 included patients, 61% achieved renal response. Using a time-varying exposure Cox model, no difference in OS between renal response and non-response was observed (HR = 1.08, 95% CI = 0.67–1.74, p = .76). In multivariable analysis, baseline eGFR <30 ml/min (HR = 1.71), age >70 yrs (HR = 1.77), hypercalcemia (HR = 2.73), lambda Bence–Jones (HR= 1.76), and initial treatment regimen (HR = 0.89 for thalidomide, HR = 1.95 in treatment regimens without novel agents and HR = 3.60 for no chemotherapy, all vs. bortezomib) were associated with decreased OS. In conclusion, achieving renal response was not associated with improved OS.